How Vaccinated Kids Infect The Non-Vaccinated

Posted on: Sunday, February 8th 2015 at 3:45 pm
Written By: <>Sayer Ji, Founder

With the thousands of mainstream media articles 
blaming the non-vaccinated for disease outbreaks, 
this article will provide a necessary 
counterbalance by showing the vaccinated can (and 
do) infect the non-vaccinated...

A groundbreaking study published in 2013 in the 
journal Vaccine titled, 
of virus shedding after lived attenuated and 
pentavalent reassortant rotavirus vaccine," 
referenced the fact that rotavirus vaccines 
contain live viruses capable of causing 
infection, shedding and even transmission to non-vaccinated subjects:

"In fact, transmission of these two rotavirus 
vaccines or vaccine-reassortment strains to 
unvaccinated contacts has been detected 
[9–13][1], even in the absence of symptoms."

One of the five studies referenced in the passage 
above confirming that the vaccinated can infect 
the non-vaccinated, 
transmission of vaccine-derived rotavirus 
(RotaTeq) associated with rotavirus 
gastroenteritis," published in 2009, is the first 
report in the literature to identify the 
transmission of rotavirus vaccine-derived virus 
to unvaccinated contacts resulting in symptomatic 
rotavirus gastroenteritis requiring emergency medical attention:

"We document here the occurrence of 
vaccine-derived rotavirus (RotaTeq [Merck and Co, 
Whitehouse Station, NJ]) transmission from a 
vaccinated infant to an older, unvaccinated 
sibling, resulting in symptomatic rotavirus 
gastroenteritis that required emergency department care."

The study also indicated that two of the five 
strains of rotavirus within the Rotateq 
reassorted to produce a more harmful virus either 
within the vaccinated infant or within the 
subsequently infected unvaccinated sibling:

"Results of our investigation suggest that 
reassortment between vaccine component strains of 
genotypes P7[5]G1 and P1A[8]G6 occurred during 
replication either in the vaccinated infant or in 
the older sibling, raising the possibility that 
this reassortment may have increased the 
virulence of the vaccine-derived virus."

This phenomenon of Rotateq vaccine strain 
reassortment and subsequent gastoenteritis 
infection in vaccine recipients was also observed 
in a 2012 study in 61 infants.[2] Additionally, A 
Nicaraguan study published in 2012 found "the 
widespread use of the RotaTeq vaccine has led to 
the introduction of vaccine genes into 
circulating human RVs.," revealing that the 
widespread introduction of the vaccine strain has 
altered the genetic makeup of wild-type rotavirus 
that now infects exposed populations.[3]

It has been estimated that between 80-100% of 
infants shed rotavirus at some point during 25-28 
days after vaccination.[4] [5] This reveals that 
the vaccinated, contrary to widespread 
assumptions about the the risks represented by 
the non-vaccinated, pose a clear risk of 
infecting the non-vaccinated, and may be 
producing the ideal virological conditions for 
the recombination of diverse rotavirus strains 
into vaccine-resistant 'super viruses.'

Another case study, reported on in the 
Vaccine Information Center's document on vaccine viral shedding:

"In 2010, a case report was published in 
Pediatrics describing a 30-month old healthy boy 
who had never received rotavirus vaccine and was 
infected with vaccine strain rotavirus. 237 He 
ended up in the emergency room with severe 
gastroenteritis 10 days after his healthy 
two-month old brother was given a dose of Merck's 
RotaTeq vaccine. A stool sample was taken in the 
emergency room and came back positive for RotaTeq 
vaccine derived strains after RT-PCR testing."

The authors of the case report noted that 
"transmission of RotaTeq strains to unvaccinated 
contacts was not evaluated in the pivotal 
[pre-licensure] clinical trials." They added 
that  both RotaTeq and Rotarix [GlaxoSmithKline 
Biologicals] vaccines have "the potential for 
vaccine-virus transmission to contacts."

The Rotateq Vaccine: Shot Through with Conflict of Interest

The Rotateq rotavirus vaccine was co-created by 
Dr. Paul Offit, widely recognized as the vaccine 
industry's leading promoter and apologist. He is 
the co-patent holder of one of two live rotavirus 
vaccines the FDA has approved, and which the 
recommends should be administered to infants in 3 
doses at ages 2 months, 4 months, and 6 months.

Historically incapable of self-recusal, despite 
his glaring conflicts of interest, Offit 
regularly positions himself as an expert on 
vaccines, even though he personally gains from 
presenting his product (and the CDC's vaccine 
schedule as a whole) as safe and effective.  Case 
in point, in one notorious interview in Parenting 
magazine he claimed a child can receive 
vaccines simultaneously without harm (corrected 
from 100,000 which he suggested in a previous interview).

The Rotavirus Vaccine Was Dirty from the Start

The first rotavirus vaccine -- Rotashield -- 
comprised of four reassorted rhesus-human 
rotaviruses was approved in 1999, only to be 
withdrawn from the market by the FDA 
months later when it was found to increase the 
risk for a deadly form of bowel obstruction known 
as intussusception in a small subset of highly vulnerable children.[6]

Offit's Rotateq, which consists of 5 reassorted 
human-bovine retroviruses (yes, that means GMO), 
was believed to be a safer alternative when it 
was approved by the FDA in 2006, but newly 
published research reveals his vaccine suffers 
from the same exact deadly problems.

Published this month in Vaccine and titled, 
risk after RotaTeq vaccination: Evaluation from 
worldwide spontaneous reporting data using a 
self-controlled case series approach", the study 
evaluated worldwide reports to the manufacturer 
of Rotateq up to May 2014, adjusting for the 
phenomenon of under-reporting.  The study found 
that the relative risk of intussception 
associated with the administration of Rotateq 
vaccine increases "3-7 days following 
vaccination, mainly after the first dose and 
marginally after the second and third 
doses."  The increase in relative risk reached 
3.45 fold in the period 3-to-7 days after the 
first dose, relative to the 15-30-day period control period.

Another study linking Rotateq to intussusception 
was published last year in the New England 
Journal of Medicine finding approximately 1.5 
(95% CI, 0.2 to 3.2) excess cases of 
intussusception per 100,000 recipients of the first dose.[7]

Live Vaccines: A Pandora's Box of Adventitious Viruses

Death or debilitation by bowel obstruction 
rapidly following Rotateq vaccination is an acute 
adverse effect that is unlikely to be overlooked 
or ignored. This is why the Vaccine Adverse 
Effects Reporting System (VAERS): a passive, 
vaccine post-marketing surveillance system, has 
found it to be a significant side effect.  VAERS, 
however, is believed to capture as little as less 
than 1% of the actual damage being done by 
vaccines, indicating that the extent of harm of 
the Rotateq is several orders of magnitude than 
presently indicated by this report.

Exposure to Rotateq therefore suffers – like many 
live vaccines – f“ from a darker side, as far as 
adverse effects go, which may take months, years, 
or decades to manifest as part of the 
multifactorial smog cloud of modern day 
toxicities and exposures that eventually make 
their way into the bottleneck of a classical diagnosis.

Rotateq, for instance, has been identified to be 
contaminated with a number of adventitious 
viruses; that is to say, viruses that 
contaminated the live cells and/or biological 
components involved in the original vaccine 
manufacturing process. These surreptitious 
agents, unknown to the manufacturers and 
regulatory agencies that approved them, infected 
the vaccines the children given them. These viruses include:

Circovirus 1 (PCV-1): In 2010 the 
suspended the Rotarix vaccine due to the 
discovery that it was contaminated with PCV-1 
virus, a pig virus, the implications of which as 
far as human exposure are still unknown. 
Considered less a risk than PCV-2, known to cause 
a debilitating wasting disease in piglets, the 
FDA determined, after review, that PCV-1 does not 
represent a risk to the millions of children exposed to it.
Circovirus 2 (PCV-2): A 2014 study conducted by 
CDC researchers and published in Human Vaccines & 
Immunotherapeutcs titled, "Detection of PCV-2 DNA 
in stool samples from infants vaccinated with 
RotaTeq®," found for the first time that PCV-2 
is shed in the stool of those vaccinated with 
Rotateq. They found "A total of 235 (28.5%) 
samples from 59 vaccine recipients were positive 
for PCV-2 DNA by one or more assays used in this 
study." Additionally, "Twenty-two of the 102 
vaccine recipients (21.6%) shed RotaTeq® vaccine 
strain and 10 of these vaccinees (9.8%) were 
shedding both PCV DNA and rotavirus vaccine 
RNA."  In pigs, PCV-2 has been linked to serious 
health problems including, "PCV2-associated 
pneumonia, PCV2-associated enteritis, 
PCV2-associated reproductive failure, and Porcine 
Dermatitis and Nephropathy Syndrome (PDNS)." 
2010, The FDA ruled, against the precautionary 
principle, that neither "PCV1 or PCV2 are known 
to infect or cause illness in humans, however PCV2 may cause illness in pigs."
endogenous strain 7 retrovirus DNA: a 2014 study 
published in Advances in Virology titled, 
"Screening of Viral Pathogens from Pediatric 
Ileal Tissue Samples after Vaccination," found 
evidence of contamination with a baboon retrovirus.
D Simian Retovirus: a 2010 study published in 
Journal of Virology revealed that the Rotateq 
vaccine contains  simian retrovirus DNA (with a 
96% match of certainty), which Judy Mikovits, 
PhD, confirms may contribute to adverse health 
effects, regardless of whether it is a self-replicating virus or not.
Because live vaccines are manufactured through 
co-culturing cells and biological fluids from 
various different species, there is plenty of 
opportunity for viruses to adapt to, 
and  recombine to produce infectious agents 
capable of far greater virulence. Rotateq is just 
one of many vaccines in the CDC's immunization 
schedule that contain live viruses capable of 
infecting those given it, including retroviruses, 
which have been called a modern-day Plague owing 
to the fact that they are capable of infecting 
the host as non-HIV acquire immunodeficiency 
viruses. For more information read 
Judy Mikovits and Kent Heckenlively's new book 
Plague or listen to this 
of Dr. Mikovits on Fearless Parent Radio.

Clearly, given the evidence revealing the 
potential unintended, adverse effects of the 
Rotateq vaccine, especially the potential for it 
to infect those exposed to it with adventitious 
viruses, the implementation of the precautionary 
principle requires the immediate suspension of 
its use until proper toxicological reevaluations 
can be made. Anyone who questions the safety of 
the present CDC immunization schedule should be 
able to point to the Rotateq as a perfect example 
of why the schedule is not at all evidence based 
but rather founded in a mythological belief in 
the safety and effectiveness of products that have never been proven sound.


  [1] [9]  Phua KB, Quak SH, Lee BW, Emmanuel SC, 
Goh P, Han HH, et al. Evaluation of RIX4414, a 
live, attenuated rotavirus vaccine, in a 
randomized, double-blind, placebo-controlled 
phase 2 trial involving 2464 Singaporean infants. 
J Infect Dis 2005;192(Suppl. 1):S6–16.
  [10]  Dennehy PH, Brady RC, Halperin SA, Ward 
RL, Alvey JC, Fischer Jr FH, et al. Comparative 
evaluation of safety and immunogenicity of two 
dosages of an oral live attenuated human 
rotavirus vaccine. Pediatr Infect Dis J 2005;24:481–8.
[11]  Payne DC, Edwards KM, Bowen MD, Keckley E, 
Peters J, Esona MD, et al. Sibling transmission 
of vaccine-derived rotavirus (RotaTeq) associated 
with rotavirus gastroenteritis. Pediatrics 2010;125:e438–41.
  [12]  Boom JA, Sahni LC, Payne DC, Gautam R, 
Lyde F, Mijatovic-Rustempasic S, et al. 
Symptomatic infection and detection of vaccine 
and vaccine-reassortant rotavirus strains in 5 
children: a case series. J Infect Dis 2012;206:1275–9.
  [13]  RRiveraL,Pen 
transmission of a human rotavirus vaccine 
strain—a randomized, placebo- controllled study 
in twins. Vaccine 2011;29:9508–13.
Infect Dis. 2012 Aug 1;206(3):377-83. doi: 
10.1093/infdis/jis361. Epub 2012 May 21.
Identification of strains of RotaTeq rotavirus 
vaccine in infants with gastroenteritis following 
routine vaccination. 
Genet Evol. 2012 Aug;12(6):1282-94. doi: 
10.1016/j.meegid.2012.03.007. Epub 2012 Apr 2.
Vaccine-derived NSP2 segment in rotaviruses from 
vaccinated children with gastroenteritis in 
[4] Phua KB, Quak SH, Lee BW, Emmanuel SC, Goh P, Han HH, et al. Evaluation of
RIX4414, a live, attenuated rotavirus vaccine, in 
a randomized, double-blind, placebo-controlled 
phase 2 trial involving 2464 Singaporean infants. 
J Infect Dis 2005;192(Suppl. 1):S6–16.
[5] Comparison of virus shedding after lived 
attenuated and pentavalent reassortant rotavirus vaccine
[6] Centers for Disease Control and Prevention. 
Intussusception among recipients of rotavirus 
vaccine—United States, 11998–1999. JAMA 
of Science
Engl J Med. 2014 Feb 6;370(6):503-12. doi: 
10.1056/NEJMoa1303164. Epub 2014 Jan 14 
Intussusception risk after rotavirus vaccination 
in U.S.